PT Suparma Tbk (SPMA) Fair Value & Analysis
Basic Materials · ID · Market cap 906B IDR
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price −4.7% over the past month.
A solid business, screening 76% undervalued on our models.
What matters now
- The price is below even our cautious bear case (215.99 IDR). The market is more pessimistic than our downside scenario.
- Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 113.16 IDR – 42,688 IDR · fair‑value band 215.99 IDR – 359.97 IDR · the 164.00 IDR price screens below the 287.98 IDR fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
PT Suparma Tbk (SPMA) currently trades at 164.00 IDR, while our model-based Fair Value estimate is 287.98 IDR, implying the stock looks roughly 75.6% undervalued today. The Quality Score stands at 50/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Suparma Tbk generated revenue of 2.8T IDR at a net margin of 3.8%. Revenue grew 2.5% year over year. It earns a return on equity of 4.2%. Net debt stands at 514B IDR. Fundamentals as of Jul 20, 2026
Our scenario range runs from 215.99 IDR (bear case) to 359.97 IDR (bull case); at 164.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Basic Materials peers we cover trades at 10% fair-value upside, at 76%, SPMA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (985.19 IDR) versus Earnings-Based (137.11 IDR). Highest evidence: Growth DCF (80).
Notify me when SPMA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Suparma Tbk manufactures and sells paper and related paper products in Indonesia. The company's paper products include laminated wrapping, coated duplex board, sandwiched ribbed kraft recycle, and brown Kraft papers; sandwiched ribbed Kraft recycle papers; and coated duplex boards.
Full company description
PT Suparma Tbk manufactures and sells paper and related paper products in Indonesia. The company's paper products include laminated wrapping, coated duplex board, sandwiched ribbed kraft recycle, and brown Kraft papers; sandwiched ribbed Kraft recycle papers; and coated duplex boards. It also offers bathroom, facial, napkin, and carrier tissues; cocktail, dinner, and luncheon napkins. In addition, the company provides hand, hand roll, industrial and clinical roll, and kitchen towels. The company was formerly known as PT Supar Inpama and changed its name to PT Suparma Tbk in December 1978. PT Suparma Tbk was founded in 1976 and is headquartered in Surabaya, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Suparma Tbk reported revenue of 2.7T IDR in FY2025 versus 2.8T IDR in FY2021, a compound −0.5%/yr. Reported net income was 106B IDR in FY2025, compounding −22.5%/yr from FY2021.
of which total revenue +5.0 pp · buybacks/dilution −2.9 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch SPMA: get an alert when its fair value changes →
Peer Group
Paper & Paper Products · 111 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Paper & Paper Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Paper & Paper Products stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Klabin S.A KLBN11 | R$17.58 | R$3.89 | -78% |
| UPM-Kymmene Oyj UPM | €23.45 | €15.47 | -34% |
| Suzano S.A SUZB3 | R$41.70 | R$138.01 | +231% |
| Svenska Cellulosa Aktiebolaget SCA (publ) SCAB | kr 103.00 | kr 49.40 | -52% |
| Shandong Sunpaper Co 002078 | ¥14.13 | ¥17.29 | +22% |
| Holmen AB HOLMB | kr 305.40 | kr 217.72 | -29% |
| Nine Dragons Paper (Holdings) Limited 2689 | HK$7.55 | HK$8.73 | +16% |
| Empresas CMPC S.A CMPC | 1,078 CLP | 1,269 CLP | +18% |
| Xianhe Co 603733 | ¥22.05 | ¥24.32 | +10% |
| Billerud AB BILL | kr 68.70 | kr 48.60 | -29% |
Compare PT Suparma Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is PT Suparma Tbk (SPMA) overvalued or undervalued?
What is the fair value of SPMA?
What is the quality score of SPMA?
What is the revenue of PT Suparma Tbk (SPMA)?
What is the net profit margin of SPMA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Suparma Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.